UCB agrees to buy Candid Therapeutics for up to $2.2 billion
Updated
Updated · The Wall Street Journal · May 4
UCB agrees to buy Candid Therapeutics for up to $2.2 billion
12 articles · Updated · The Wall Street Journal · May 4
The Brussels-based drugmaker will pay $2 billion upfront plus up to $200 million in milestones, with closing expected by late second quarter or early third quarter.
UCB said privately held Candid’s lead asset, cizutamig, is a bispecific antibody in multiple early-stage trials for autoimmune and inflammatory diseases.
The deal extends UCB’s recent business-development push after March’s Antengene licensing pact and last month’s Neurona acquisition, while the company said its 2026 guidance remains unchanged.
With a patent cliff looming, is UCB's $2.2B high-risk acquisition the new blueprint for pharmaceutical survival?
Can a drug that weaponizes the immune system cure autoimmunity without causing catastrophic friendly fire?